Medical-device executives are optimistic that the market for cardiac resynchronization therapy devices and other expensive implants could double if the MADIT-CRT study yields positive results. The Boston Scientific-sponsored study aims to show that combining defibrillators with CRT devices could delay the progression of early-stage heart failure. An analyst with FAF Advisors, however, said reimbursement will play a key role in boosting the sales of the combination products.

Full Story:

Related Summaries